FDA Asks: Better Ways to Track Rare Disease Drugs?
Published Date: 4/16/2026
Notice
Summary
The FDA wants your thoughts on how it collects info about orphan drugs—special medicines for rare diseases. They’re asking for comments by June 15, 2026, to make sure the process is clear and not too complicated. This helps keep things running smoothly without extra costs or delays for drug makers and patients.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Seven-Year Orphan Drug Exclusivity
Under section 527 of the Federal Food, Drug, and Cosmetic Act, a sponsor that receives an orphan drug designation may obtain exclusive FDA marketing approval for that orphan indication for a period of 7 years. This exclusivity is tied to orphan drug approval and is intended to protect the sponsor's market for that indication.
Large Time Burden for Orphan Submissions
FDA estimates the annual information-collection burden for orphan drug-related records and submissions totals 193,830 hours across respondents, covering designation requests, amendments, annual reports, and meeting materials. FDA also says its burden estimate reflects a nominal increase of approximately 9% annually.
Open Protocols Let Patients Access Trials
Section 528 encourages sponsors to make investigational orphan drugs available for treatment on an open protocol basis before full approval, allowing patients who are not part of the formal clinical investigation to obtain treatment where adequate supplies exist and no alternative effective therapy is available. This can increase earlier access to investigational treatments for people in need of rare-disease therapies.
Possible Fee to Encrypt Email Submissions
FDA recommends sponsors use an FDA-secured email address for private or confidential submissions and says there may be a fee to a commercial enterprise for establishing a digital certificate before encrypted emails can be sent to FDA. This could add a one-time or periodic cost for commercial submitters who choose encrypted email transmission.
Form FDA 4035 Simplifies Orphan Requests
FDA includes Form FDA 4035, the Orphan Drug Designation Request Form, as a simplified method for sponsors to provide only the information required by Sec. 316.20 for FDA decision making. The form is intended to benefit sponsors seeking orphan designation by streamlining required information.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07422 — Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT
The FDA has set the official review period for UNLOXCYT, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind UNLOXCYT and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s effort during review, you have until mid-2026 to speak up—potentially impacting patent length and market exclusivity.
Next: 2026-07424 — Sunshine Act Meetings
The Neighborhood Reinvestment Corporation is holding a board meeting on April 16, 2026, via Zoom, with some parts open to the public and others closed for privacy. They’ll discuss important topics like audits, contracts, and financial reports, plus approve key actions like a temporary board chair and health insurance delegation. This update affects board members and anyone interested in the corporation’s transparency and governance, with no direct cost changes announced.